Lcm Capital Management Inc Biogen Inc. Transaction History

Lcm Capital Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$190.52 - $236.72 $176,802 - $219,676	928 New	928 $215,000
Q4 2023 Feb 05, 2024	SELL	$222.59 - $267.94 $890 - $1,071	-4 Reduced 0.43%	924 $239,000
Q3 2023 Nov 07, 2023	BUY	$253.3 - $285.89 $10,132 - $11,435	40 Added 4.5%	928 $238,000
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $1,926 - $2,226	7 Added 0.79%	888 $252,000
Q1 2023 May 01, 2023	BUY	$256.56 - $292.34 $11,032 - $12,570	43 Added 5.13%	881 $244,000
Q4 2022 Jan 24, 2023	BUY	$252.44 - $306.72 $1,009 - $1,226	4 Added 0.48%	838 $0
Q3 2022 Oct 14, 2022	BUY	$194.69 - $268.46 $162,371 - $223,895	834 New	834 $223,000
Q4 2021 Jan 24, 2022	SELL	$223.92 - $287.77 $178,688 - $229,640	-798 Closed	0 $0
Q3 2021 Oct 15, 2021	SELL	$282.99 - $369.05 $2,546 - $3,321	-9 Reduced 1.12%	798 $226,000
Q2 2021 Jul 21, 2021	SELL	$259.0 - $414.71 $3,108 - $4,976	-12 Reduced 1.47%	807 $279,000
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $13,605 - $15,939	-56 Reduced 6.4%	819 $229,000
Q4 2020 May 12, 2021	BUY	$236.26 - $355.63 $206,727 - $311,176	875 New	875 $209,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Lcm Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Lcm Capital Management Inc with notifications on news.